InDex Pharmaceuticals (private company)

See something wrong or missing? Let us know
Offices:
Stockholm
Category:
Pharma
Business model:
B2B
Investors:
we tracked 2 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 2 transactions

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

InDex conducts drug development and is located at Karolinska Institutet Science Park, in Stockholm.

The Company’s lead asset is cobitolimod, which is in late stage clinical development for moderate to severe active ulcerative colitis, a debilitating, chronic inflammation of the large intestine. In addition, InDex has a broad portfolio of other DNA based ImmunoModulatory Sequences (DIMS) in discovery stage, with the potential to be used in the treatment of various immunological diseases.

InDex is a pharmaceutical development company, which means that the Company develops compounds from pre-clinical through clinical phases, with the strategy to out license the compounds during late stage clinical development for the concluding development work, regulatory approval and commercialisation.

Companies with similar profile to InDex Pharmaceuticals:

CompanyCriteria
Sweden OxThera
45%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Athera
35%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
Sweden Trialbee
35%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
Sweden Apica
34%
  • Similar business models: B2B
  • At least one vc investor: SEB Venture Capital, Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Sol Voltaics
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden AMRA
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Funnel
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Iceland Meniga
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Clavister
34%
  • Similar business models: B2B
  • At least one vc investor: SEB Venture Capital, Industrifonden
  • Total raised in a similar range: 10M+ USD
Norway poLight
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden inRiver
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden BoneSupport
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Airsonett
34%
  • Similar business models: B2B
  • At least one vc investor: SEB Venture Capital, Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Starcounter
34%
  • Similar business models: B2B
  • At least one vc investor: Industrifonden
  • Total raised in a similar range: 10M+ USD
Sweden Asarina Pharma
33%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Finland Aurealis Pharma
33%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Norway Vaccibody
33%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Sweden Pharmalink
33%
  • Similar verticals: Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Denmark Coinify
24%
  • Similar business models: B2B
  • At least one vc investor: SEB Venture Capital
Sweden Avidicare
24%
  • Similar business models: B2B
  • At least one vc investor: SEB Venture Capital